ArticleJournal of inflammation research2025
Genetic Association and Drug Target Exploration Between Inflammation-Related Proteins and the Risk of Primary Ovarian Insufficiency.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Restoring glucose metabolic homeostasis to attenuate ovarian aging: mechanisms and clinical prospects.Journal of ovarian research · 2026Review
- Identification of Biomarker in Kidney Stone Disease by Integrating Transcriptomics and Olink Proteomics: A Case-Control Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Primary ovarian insufficiency (POI) exhibits ovarian dysfunction characteristics, which develops from diminished ovarian reserve (DOR). However, the pathogenesis remains unclear. In this study, we aimed to analyze the causal relationship between inflammation-related proteins and the occurrence of POI at the genetic level, and to identify potential druggable gene targets from inflammation-related genes. Patients and Methods: We conducted a Mendelian randomization (MR) analysis to explore causal association for inflammation-related proteins and POI. Genetic instruments for 91 inflammation-related proteins were derived from the Olink Results: Via inverse-variance weighted (IVW) method, our study identified two proteins, CXCL10 and CX3CL1 might exert protective effects against POI; whereas IL-18R1, IL-18, MCP-1, and CCL28 might increase the risk of POI. Moreover, Wald ratio analyses highlighted additional protective proteins, such as IL-17C, TRANCE, uPA, LAP TGF-β1, and CXCL9; along with risk proteins, including TNFSF14, CD40, IL-24, ARTN, LIF-R, and IL-2RB. Meanwhile, MCP-1/CCL2, TGFB1, ARTN, and LIFR were significantly changed in the POI model, which converged in the oncostatin M signaling pathway. Notably, gene-drug analysis identified CCL2 and TGFB1 as potential therapeutic targets, whereas genistein and melatonin were prioritized as potential drugs for POI treatment. Conclusion: Our study highlights the causal role of specific inflammation-related proteins in POI, advancing our understanding of its etiology, and further extends the therapeutic options for improving ovarian function and delaying POI onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.